Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 263

1.

Etanercept as monotherapy in patients with psoriasis.

Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB; Etanercept Psoriasis Study Group..

N Engl J Med. 2003 Nov 20;349(21):2014-22.

2.

A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.

Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, Zitnik R, van de Kerkhof PC, Melvin L; Etanercept Psoriasis Study Group..

Br J Dermatol. 2005 Jun;152(6):1304-12.

PMID:
15948997
3.

Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.

Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, Jahreis A.

Arch Dermatol. 2007 Jun;143(6):719-26.

PMID:
17576937
4.

Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.

Gordon K, Korman N, Frankel E, Wang H, Jahreis A, Zitnik R, Chang T.

J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S101-11.

PMID:
16488320
5.

Etanercept treatment for children and adolescents with plaque psoriasis.

Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I, Hebert AA, Eichenfield LF, Patel V, Creamer K, Jahreis A; Etanercept Pediatric Psoriasis Study Group..

N Engl J Med. 2008 Jan 17;358(3):241-51. doi: 10.1056/NEJMoa066886.

6.

Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.

van de Kerkhof PC, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A, Leigheb G, Camacho FM, Forsea D, Zang C, Boussuge MP, Paolozzi L, Wajdula J.

Br J Dermatol. 2008 Nov;159(5):1177-85. doi: 10.1111/j.1365-2133.2008.08771.x. Epub 2008 Jul 31.

PMID:
18673365
7.

Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.

Krueger GG, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D, Jahreis A.

Br J Dermatol. 2005 Dec;153(6):1192-9.

PMID:
16307657
8.

A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.

Moore A, Gordon KB, Kang S, Gottlieb A, Freundlich B, Xia HA, Stevens SR.

J Am Acad Dermatol. 2007 Apr;56(4):598-603. Epub 2006 Nov 17.

PMID:
17113190
9.

A randomized trial of etanercept as monotherapy for psoriasis.

Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, Gaspari AA, Ling M, Weinstein GD, Nayak A, Gordon KB, Zitnik R.

Arch Dermatol. 2003 Dec;139(12):1627-32; discussion 1632.

PMID:
14676082
10.

Treatment of erythrodermic psoriasis with etanercept.

Esposito M, Mazzotta A, de Felice C, Papoutsaki M, Chimenti S.

Br J Dermatol. 2006 Jul;155(1):156-9.

PMID:
16792768
11.

Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis.

Landells I, Paller AS, Pariser D, Kricorian G, Foehl J, Molta C, Freundlich B.

Eur J Dermatol. 2010 May-Jun;20(3):323-8. doi: 10.1684/ejd.2010.0911. Epub 2010 Feb 25.

PMID:
20185386
12.

Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis.

Elewski B, Leonardi C, Gottlieb AB, Strober BE, Simiens MA, Dunn M, Jahreis A.

Br J Dermatol. 2007 Jan;156(1):138-42.

PMID:
17199580
13.

Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.

Mazzotta A, Esposito M, Costanzo A, Chimenti S.

Am J Clin Dermatol. 2009;10(5):319-24. doi: 10.2165/11310770-000000000-00000.

PMID:
19658444
14.

Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis.

Reich K, Segaert S, Van de Kerkhof P, Durian C, Boussuge MP, Paolozzi L, Wajdula J, Boggs R.

Dermatology. 2009;219(3):239-49. doi: 10.1159/000237871. Epub 2009 Sep 10.

PMID:
19752505
15.

Two years of experience with etanercept in recalcitrant psoriasis.

Ahmad K, Rogers S.

Br J Dermatol. 2007 May;156(5):1010-4. Epub 2007 Apr 4.

PMID:
17408393
16.

Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.

Sterry W, Ortonne JP, Kirkham B, Brocq O, Robertson D, Pedersen RD, Estojak J, Molta CT, Freundlich B.

BMJ. 2010 Feb 2;340:c147. doi: 10.1136/bmj.c147.

17.

Treating psoriasis with etanercept in italian clinical practice: prescribing practices and duration of remission following discontinuation.

Arcese A, Aste N, Bettacchi A, Camplone G, Cantoresi F, Caproni M, D'Amico D, Fabbri P, Filosa G, Galluccio A, Hansel K, Lisi P, Micali G, Musumeci ML, Nicolini M, Parodi A, Patania M, Pezza M, Potenza C, Richetta A, Simonacci M, Trevisan P, Valenti G, Calvieri S.

Clin Drug Investig. 2010;30(8):507-16. doi: 10.2165/11537470-000000000-00000.

PMID:
20586516
18.

Etanercept for the treatment of psoriasis: combination therapy with other modalities.

Strober BE, Clarke S.

J Drugs Dermatol. 2004 May-Jun;3(3):270-2.

PMID:
15176161
19.

Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept.

Bagel J, Lynde C, Tyring S, Kricorian G, Shi Y, Klekotka P.

J Am Acad Dermatol. 2012 Jul;67(1):86-92. doi: 10.1016/j.jaad.2011.07.034. Epub 2011 Oct 20.

PMID:
22014541
20.

Our experience with etanercept in the treatment of psoriasis.

Kokelj F, Miertusova Tothova S, Patamia M, Trevisan G.

Acta Dermatovenerol Croat. 2006;14(4):241-5.

PMID:
17311738

Supplemental Content

Support Center